Search Results - "Heffernan, T.P"

Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results by Barve, M, Grosen, E.A, Fine, B.A, Heffernan, T.P, Matthews, C.M, Stringer, C.A, Koon, E.C, Goodman, H.M, Fleming, E.L, DeMars, L.R, Bergman, M.S, Senzer, N, Nemunaitis, J

Get full text

100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications by Tedeschi, A., Peng, D.H., Schischlik-Siegl, F., Schaaf, O., Gerlach, D., Rocchetti, F., Popow, J., Broeker, J., Wunberg, T., Boghossian, A.S., Rees, M.G., Ronan, M.M., Roth, J.A., Williams, M., Vellano, C., Marszalek, J.R., Heffernan, T.P., Pearson, M., Kraut, N., Dorothea, R.

Get full text

126 (PB114): A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer by Jung, P., Glaser, S.P., Han, J., Popa, A., Pisarsky, L., Feng, N., Geyer, A., Haderk, F., Alpar, D., Bristow, C., Drobits-Handl, B., Kasturirangan, S., Trapani, F., Marszalek, J.R., Tontsch-Grunt, U., Pearson, M., Heffernan, T.P., Kraut, N., Vellano, C.P., García-Martínez, J.M.

Get full text

MEKi-based combination strategies for targeting KRAS-driven cancer by Kostyrko, K., Hinkel, M., Traexler, P.E., Arnold, D., Melo-Zainzinger, G., Gerlach, D., Ruzicka, R., Jacob, R., Baum, A., Lu, H., Vellano, C.P., Marszalek, J.R., Heffernan, T.P., Tontsch-Grunt, U., Hofmann, M.H.

Get full text

HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome by Wardwell-Ozgo, J, Dogruluk, T, Gifford, A, Zhang, Y, Heffernan, T P, van Doorn, R, Creighton, C J, Chin, L, Scott, K L

“…Melanoma is a highly lethal malignancy notorious for its aggressive clinical course and eventual resistance to existing therapies. Currently, we possess a…”
Get full text

Vertical pathway inhibition with a SOS1::KRAS inhibitor enhances the efficacy of KRAS G12C inhibitors, delays feedback resistance and demonstrates durable response by Savarese, F., Gmachl, M., Federico, L., Trapani, F., Gerlach, D., Daniele, J., Feng, N., Bristow, C.A., Machado, A., Huang, J., Rudolph, D., Waizenegger, I., Ramharter, J., Vellano, C.P., Petronczki, M., Marszalek, J.R., Heffernan, T.P., McConnell, D.B., Kraut, N., Hofmann, M.

Get full text